AZ amps up respiratory battle with Breztri trial win by Kyle Blankenship Wednesday, August 28, 2019 AstraZeneca and GlaxoSmithKline have locked horns in their battle for respiratory supremacy. Could a trial win and an FDA nod help give AZ a leg up?
GlaxoSmithKline's Nucala scores convenience boost by Carly Helfand Friday, June 7, 2019 GlaxoSmithKline’s Nucala has suffered against a more convenient AstraZeneca rival, but the company finally has an answer.
Novartis' Xolair eyes sinusitis to backstop blockbuster sales by Kyle Blankenship Tuesday, June 4, 2019 Facing stiff competition in asthma, Novartis’ Xolair can use all the help it can get to keep its blockbuster status. Could sinusitis be the cure?
AZ's Fasenra benefits hold up for 2 years: analysis by Eric Sagonowsky Monday, May 20, 2019 AstraZeneca has released data showing its med's effects can last up to two years in severe asthma.
